Skip to main content

Advertisement

SpringerLink
Log in

Bisphosphonates for malignancy-related bone disease: current status, future developments

  • Review Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

This review relates to the efficacy and safety of bisphosphonates in metastatic bone disease. It discusses practical recommendations and possible future indications for bisphosphonate therapy. The current aims of bisphosphonates for metastatic bone disease are to prevent skeletal-related events (SREs), reduce bone pain and improve quality of life. Phase III clinical trials of clodronate and pamidronate have established their efficacy against bone complications in patients with breast cancer and multiple myeloma, while randomized trials have shown SRE reductions with zoledronic acid in patients with breast cancer and multiple myeloma, prostate cancer, and lung and other solid tumors. These bisphosphonates also have some effect on metastatic bone pain. Ibandronate is a new aminobisphosphonate, available in more than 40 countries outside of the US as intravenous and oral formulations for the prevention of skeletal events in patients with breast cancer and bone metastases. Phase III studies have shown that both intravenously and orally administered ibandronate have efficacy for the prevention of skeletal events and for the reduction of metastatic bone pain. In addition to efficacy, the long-term tolerability of bisphosphonates in metastatic bone disease influences drug selection. Besides their use in patients with established bone metastases, recent and ongoing research suggests that bisphosphonates also have clinical benefit in the adjuvant setting, and for the treatment of cancer-treatment-induced bone loss. Such interesting new developments may underpin a new era of bisphosphonate use sometime in the near future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rubens RD (2000) Clinical aspects of bone metastases. In: Body JJ (ed) Tumor bone diseases and osteoporosis in cancer patients. Marcel Dekker, New York, pp 85–96

    Google Scholar 

  2. Cleeland CS, Janjan NA, Scott CB et al (2000) Cancer pain management by radiotherapists: a survey of radiation therapy oncology group physicians. Int J Radiat Oncol Biol Phys 47:203–208

    PubMed  CAS  Google Scholar 

  3. Body JJ (2004) Hypercalcemia of malignancy. Semin Nephrol 24:48−54

    Article  PubMed  Google Scholar 

  4. Green JR (2003) Antitumor effects of bisphosphonates. Cancer 97:840–847 (Suppl)

    Article  PubMed  Google Scholar 

  5. Fromigue O, Kheddoumi N, Body JJ (2003) Bisphosphonates antagonize bone growth factors effects on human breast cancer cells survival. Br J Cancer 89:178−184

    Article  PubMed  CAS  Google Scholar 

  6. Santini D, Vespasiani Gentilucci U, Vincenzi B et al (2003) The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 14:1468−1476

    Article  PubMed  CAS  Google Scholar 

  7. Kanis JA, Powles T, Paterson AH et al (1996) Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 19:663–667

    Article  PubMed  CAS  Google Scholar 

  8. Paterson AHG, Powles TJ, Kanis JA et al (1993) Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11:59–65

    PubMed  CAS  Google Scholar 

  9. Body JJ, Dumon JC, Piccart M, Ford J (1995) Intravenous pamidronate in patients with tumor-induced osteolysis: a biochemical dose-response study. J Bone Miner Res 10:1191–1196

    Article  PubMed  CAS  Google Scholar 

  10. McCloskey BV, Dunn JA, Kanis JA et al (2001) Long-term follow up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol 113:1035–1043

    Article  PubMed  CAS  Google Scholar 

  11. Tubiana-Hulin M, Beuzeboc P, Mauriac L et al (2001) Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull Cancer 88:701–707

    PubMed  CAS  Google Scholar 

  12. Robertson A, Reed N, Ralston S (1995) Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncol 13:2427–2430

    PubMed  CAS  Google Scholar 

  13. Hortobagyi G, Theriault R, Lipton A et al (1998) Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 16:2038–2044

    PubMed  CAS  Google Scholar 

  14. Hillner BE, Weeks JC, Desch CE, Smith TJ (2000) Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 18:72–79

    PubMed  CAS  Google Scholar 

  15. Lipton A, Theriault RL, Hortobagyi GN et al (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer 88:1082–1090

    Article  PubMed  CAS  Google Scholar 

  16. Theriault RL, Lipton A, Hortobagyi GN et al (1999) Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol 17:846−854

    PubMed  CAS  Google Scholar 

  17. Lipton A (2003) Bisphosphonates and metastatic breast carcinoma. Cancer 97:848–853 (Suppl)

    Article  PubMed  Google Scholar 

  18. Jagdev SP, Purohito P, Heatley S, Herling C, Coleman RE (2001) Comparison of the effect of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol 12:1433–1438

    Article  PubMed  CAS  Google Scholar 

  19. Rosen LS, Gordon D, Kaminski M et al (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7:377–387

    PubMed  CAS  Google Scholar 

  20. Rosen LS, Gordon D, Kaminski M et al (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98:1735–1744

    Article  PubMed  CAS  Google Scholar 

  21. Rosen LS, Gordon D, Tchekmedyian S et al (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial − the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150–3157

    Article  PubMed  CAS  Google Scholar 

  22. Rosen L, Gordon D, Tchekmediyan S et al (2004) Long-term zoledronic acid therapy is effective and safe for reducing the risk of skeletal complications in patients with non-small cell lung cancer (NSCLC) and bone metastases. Bone 34(Suppl 1):S89 (abstract 73)

    Google Scholar 

  23. Saad F, Gleason D, Murray R et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458–1468

    PubMed  CAS  Google Scholar 

  24. Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879–882

    PubMed  CAS  Google Scholar 

  25. Lipton A, Zheng M, Seaman J (2003) Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 98:962–969

    Article  PubMed  CAS  Google Scholar 

  26. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO (2003) Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 21:4277–4284

    Article  PubMed  CAS  Google Scholar 

  27. Lipton A, Seaman J, Zheng M (2004) Long-term efficacy and safety of zoledronic acid in patients with bone metastases from renal cell carcinoma. Bone 24(Suppl 1):S62 (abstract 28)

    Google Scholar 

  28. Body JJ, Diel IJ, Lichinitser MR et al (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14:1399–1405

    Article  PubMed  Google Scholar 

  29. Body JJ, Diel IJ, Lichinitzer M et al (2004) Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 90:1133–1137

    Article  PubMed  CAS  Google Scholar 

  30. Fulfaro F, Casuccio A, Ticozzi C, Ripamonti C (1998) The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain 78:157−169

    Article  PubMed  CAS  Google Scholar 

  31. Kohno N, Aogi K, Minami H et al (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol (in press)

    Google Scholar 

  32. Diel IJ, Body JJ, Lichinitser MR et al (2004) Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 40:1704–1712

    Article  PubMed  CAS  Google Scholar 

  33. Body JJ, Diel IJ, Bell R et al (2004) Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 111:306–312

    Article  PubMed  CAS  Google Scholar 

  34. Coleman R, Rubens R (1987) The clinical course of bone metastases from breast cancer. Br J Cancer 55:61−66

    PubMed  CAS  Google Scholar 

  35. Diel IJ, Solomayer EF, Bastert G (2000) Treatment of metastatic bone disease in breast cancer: bisphosphonates. Clin Breast Cancer 1:43–51

    Article  PubMed  CAS  Google Scholar 

  36. Body J (2001) Dosing regimens and main adverse events of bisphosphonates. Semin Oncol 28(Suppl 11):49–53

    Article  PubMed  CAS  Google Scholar 

  37. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527–534

    Article  PubMed  Google Scholar 

  38. Zojer N, Keck AV, Pecherstorfer M (1999) Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf 21:389−406

    Article  PubMed  CAS  Google Scholar 

  39. Chang JT, Green L, Beitz J (2003) Renal failure with the use of zoledronic acid. N Engl J Med 349:1676–1679

    Article  PubMed  CAS  Google Scholar 

  40. Bell R, Body JJ, Bergström B (2004) Renal safety of intravenous ibandronate for up to 4 years in patients with breast cancer and bone metastases. Breast Cancer Res Treat 88(Suppl 1):S132 (abstract 3058)

    Google Scholar 

  41. Neugebauer G, Kohler W, Akinkunmi L et al (2001) Influence of peak ibandronic acid concentrations after 6 mg IV administration with shortened infusion time (15 and 30 minutes) on renal safety in man. Proc Am Soc Clin Oncol 20:122a (abstract 486)

    Google Scholar 

  42. Body JJ, Lichinitser M, Andreeva N et al (2004) Safety of an intravenous (i.v.) dose of ibandronate followed by daily oral dosing in metastatic bone disease: results of an open-label study. Proc Am Soc Clin Oncol 23:60 (abstract 735)

    Google Scholar 

  43. Body J, Mancini I (2002) Bisphosphonates for cancer patients: why, how, and when? Support Care Cancer 10:399–407

    Article  PubMed  CAS  Google Scholar 

  44. Kaminski M, Rosen L, Gordon D et al (2004) Zoledronic acid versus pamidronate in patients with breast cancer and multiple myeloma who are at high risk for skeletal complications. Proc Am Soc Clin Oncol 23:90 (abstract 857)

    Google Scholar 

  45. Hillner BE, Ingle JN, Chlebowski RT et al (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042–4057

    Article  PubMed  CAS  Google Scholar 

  46. Mashiba T, Hirano T, Turner CH et al (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15:613–620

    Article  PubMed  CAS  Google Scholar 

  47. Vinholes JJF, Prakash Purohit O, Abbey ME, Eastell R, Coleman RE (1997) Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol 8:1243−1250

    Article  PubMed  CAS  Google Scholar 

  48. Lipton A, Costa L, Ali S, Demers L (2001) Use of markers of bone turnover for monitoring bone metastases and the response to therapy. Semin Oncol 28:54–59

    Article  PubMed  CAS  Google Scholar 

  49. Body JJ, Dumon JC, Gineyts E, Delmas PD (1997) Comparative evaluation of markers of bone resorption in patients with breast-cancer induced osteolysis before and after bisphosphonate therapy. Br J Cancer 75:408–412

    PubMed  CAS  Google Scholar 

  50. Brown JE, Thomson CS, Ellis SP, Gutcher SA, Purohit OP, Coleman RE (2003) Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 89:2031–2037

    Article  PubMed  CAS  Google Scholar 

  51. Brown JE, Cook RJ, Major P et al (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97:59–69

    Article  PubMed  CAS  Google Scholar 

  52. Costa L, Demers LM, Gouveia-Oliveira A et al (2002) Prospective evaluation of the peptide bound collagen type 1 cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 20:850–856

    Article  PubMed  CAS  Google Scholar 

  53. Garnero P (2001) Markers of bone turnover in prostate cancer. Cancer Treat Rev 27:187−192 (discussion 193−196)

    Article  PubMed  CAS  Google Scholar 

  54. De Cock E, Hutton J, Canney P et al (2005) Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy. Support Care Cancer (in press)

  55. Berenson J, Hillner B, Kyle R et al (2002) American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncology 20:3719–3736

    Article  Google Scholar 

  56. Berenson JR, Vescio R, Henick K et al (2001) A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer 91:144–154

    Article  PubMed  CAS  Google Scholar 

  57. Berenson JR, Vescio RA, Rosen LS et al (2001) A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin Cancer Res 7:478–485

    PubMed  CAS  Google Scholar 

  58. Body JJ, Lichinitser M, Tjulandin SA, Budde M, Bergström B (2005) Effect of oral ibandronate versus intravenous (i.v.) zoledronic acid on markers of bone resorption in patients with breast cancer and bone metastases: results from a comparative phase III trial. Proc Am Soc Clin Oncol 23:12S (abstract 534)

    Google Scholar 

  59. Heidenreich A, Elert A, Hofmann R (2002) Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis 5:231–235

    Article  PubMed  CAS  Google Scholar 

  60. Heidenreich A, Ohlmann C, Olbert P, Hegele A (2003) High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer. Eur J Cancer 1(Suppl 5):S270

    Google Scholar 

  61. Mancini I, Dumon JC, Body JJ (2004) Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. J Clin Oncol 22:3587–3592

    Article  PubMed  CAS  Google Scholar 

  62. Clohisy DR, Mathyh PW (2003) Bone cancer pain. Cancer 97(Suppl 3):866–873

    Article  PubMed  Google Scholar 

  63. Yau V, Chow E, Davis L et al (2004) Pain management in cancer patients with bone metastases remains a challenge. J Pain Symptom Manage 27:1–3

    Article  PubMed  Google Scholar 

  64. Novartis Pharma. Zometa (zoledronic acid). US prescribing information. November 2004

  65. Balla J (2005) The issue of renal safety with zoledronic acid from a nephrologist’s point of view. Oncologist 10:306–368

    Article  PubMed  Google Scholar 

  66. Pavlakis N, Stockler M (2002) Bisphosphonates for breast cancer. Cochrane Database System Rev:CD003474

    Google Scholar 

  67. Tripathy D, Body JJ, Diel I, Bergstrom B (2004) Intravenous and oral ibandronate reduce the risk of skeletal-related events (SREs) in patients with breast cancer and bone metastases. Eur J Cancer (Suppl 2):138

    Google Scholar 

  68. Ernst DS, Brasher P, Hagen N (1997) A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. J Pain Symptom Manage 13:319−326

    Google Scholar 

  69. Koeberle D, Bacchus L, Thuerlimann B et al (1999) Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial. Support Care Cancer 7:21−27

    Article  PubMed  CAS  Google Scholar 

  70. Ohlmann C, Heidenreich A (2003) Ibandronate in the palliative management of urological malignancies with compensated renal insufficiency. Support Care Cancer 11:413 (abstract A-97)

    Google Scholar 

  71. Body JJ, Mancini I, Dumon JC (2004) Intensive intravenous ibandronate treatment significantly relieves opioid-resistant bone pain and improves quality of life in patients with skeletal metastases. Eur J Cancer (Suppl 2):133

    Google Scholar 

  72. Diel IJ, Solomayer EF, Costa SD et al (1998) Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339:357–363

    Article  PubMed  CAS  Google Scholar 

  73. Saarto T, Blomqvist C, Virkkunen P, Elomaa I (2001) Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 19:10–17

    PubMed  CAS  Google Scholar 

  74. Saarto T, Vehmanen L, Blomqvist C et al (2004) Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment. Proc Am Soc Clin Oncol 23:8 (abstract 527)

    Google Scholar 

  75. Powles T, Paterson S, Kanis J et al (2002) Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 20:3219–3224

    Article  PubMed  CAS  Google Scholar 

  76. Powles T, Paterson A, McCloskey E et al (2004) Oral clodronate for adjuvant treatment of operable breast cancer: results of a randomized, double-blind, placebo-controlled multicenter trial. Proc Am Soc Clin Oncol 23:9 (abstract 528)

    Google Scholar 

  77. Jaschke A, Bastert G, Solomayer EF et al (2004) Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow—a longtime follow-up. Proc Am Soc Clin Oncol 23:9 (abstract 529)

    Google Scholar 

  78. Kokufu I, Kohno N, Takao S et al (2004) Adjuvant pamidronate therapy for the prevention of bone metastasis in breast cancer patients with four or more positive nodes. Proc Am Soc Clin Oncol 23:8 (abstract 530)

    Google Scholar 

  79. Coleman R, Gralow J, Bell R et al (2004) Zoledronic acid is being investigated for the prevention of bone metastases in patients with early stage breast cancer. Bone 34(Suppl 1):S85

    Google Scholar 

  80. Bauss F, Russell RGG (2004) Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int 15:423–433

    Article  PubMed  CAS  Google Scholar 

  81. Powles TJ, McCloskey E, Paterson AH et al (1998) Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst 90:704–708

    Article  PubMed  CAS  Google Scholar 

  82. Vehmanen L, Saarto T, Elomaa I et al (2001) Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur J Cancer 37:2373–2378

    Article  PubMed  CAS  Google Scholar 

  83. Rizzoli R, Forni M, Schaad MA et al (1996) Effects of oral clodronate on bone mineral density in patients with relapsing breast cancer. Bone 18:531–537

    Article  PubMed  CAS  Google Scholar 

  84. Delmas PD, Balena R, Confravreux E et al (1997) Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 15:955–962

    PubMed  CAS  Google Scholar 

  85. Gant M, Hausmaninger H, Samonigg H et al (2002) Changes in bone mineral density caused by anastrazole or tamoxifen in combination with goserelin (+/− zoledronate) as adjuvant treatment for hormone receptor positive premenopausal breast cancer: results of a randomised multicenter trial. Breast Cancer Res Treat 76(Suppl 1):S31

    Google Scholar 

  86. Theriault R, Jakesz R, Gnant M et al (2004) The evolving role of bisphosphonates for the prevention of cancer treatment-induced bone loss in patients with breast cancer. Bone 34(Suppl 1):S90

    Google Scholar 

  87. Smith MR, McGovern FJ, Zietman AL et al (2001) Pamidronate to prevent bone loss in men receiving gonadotropin releasing hormone agonist therapy for prostate cancer. N Engl J Med 345:948–955

    Article  PubMed  CAS  Google Scholar 

  88. Smith MR, Eastham J, Gleason DM et al (2003) Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169:2008–2012

    Article  PubMed  CAS  Google Scholar 

  89. Smith M (2003) Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer. Drugs Aging 20:175–183

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

    Jean-Jacques Body

Authors
  1. Jean-Jacques Body
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean-Jacques Body.

Additional information

Professor Body has received honoraria and grant support from Hoffmann-La Roche, and grant support from Novartis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Body, JJ. Bisphosphonates for malignancy-related bone disease: current status, future developments. Support Care Cancer 14, 408–418 (2006). https://doi.org/10.1007/s00520-005-0913-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-005-0913-5

Keywords

Search

Navigation